CN Patent

CN116173003A — 药物吉维司他在治疗阿尔茨海默病中的用途

Assigned to Shanxi Medical University · Expires 2023-05-30 · 3y expired

What this patent protects

本发明属于医药技术领域，具体涉及药物吉维司他在治疗阿尔茨海默病中的用途。本发明首次尝试将吉维司他用于治疗阿尔茨海默病，通过行为学实验和电生理记录手段系统观察了吉维司他的神经保护作用，结果显示，吉维司他能够改善APP/PS1双转小鼠的自主探究行为、长期空间学习、参考记忆能力以及突触可塑性损伤，说明吉维司他能够对阿尔茨海默病具有明显的治疗效果。

USPTO Abstract

本发明属于医药技术领域，具体涉及药物吉维司他在治疗阿尔茨海默病中的用途。本发明首次尝试将吉维司他用于治疗阿尔茨海默病，通过行为学实验和电生理记录手段系统观察了吉维司他的神经保护作用，结果显示，吉维司他能够改善APP/PS1双转小鼠的自主探究行为、长期空间学习、参考记忆能力以及突触可塑性损伤，说明吉维司他能够对阿尔茨海默病具有明显的治疗效果。

Drugs covered by this patent

givinostat-hydrochloride (GIVINOSTAT HYDROCHLORIDE)

Patent Metadata

Patent number: CN116173003A
Jurisdiction: CN
Classification: —
Expires: 2023-05-30
Drug substance claim: No
Drug product claim: No
Assignee: Shanxi Medical University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.